A Phase 1 interventional study of TAK-228 and TAK-117 in Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-30.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic malignancies.
The drug being tested in this study was TAK-228. TAK-228 was tested to evaluate the safety, pharmacokinetics and efficacy, of TAK-228 in combination with TAK-117 when administered to adult participants with advanced nonhematologic malignancies.
The study enrolled 101 patients. The study consisted of 2 phases: an escalation stage followed by an expansion stage. Participants in escalation stage were assigned to the following treatment arms:
Upon completion of the escalation stage, 1 combination treatment regimen was selected for further safety, tolerability, pharmacokinetics, and mutual drug-drug interaction characterization in the expansion stage. During treatment, participants in both stages received TAK-228 and TAK-117 capsules at prespecified doses in repeated 28-day cycles.
This multi-center trial conducted in the United States, United Kingdom and Spain. The overall time to participate in this study was approximately 68 weeks. Participants made multiple visits to the clinic, and a final visit after 30 days after last dose of study drug.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
Drug: TAK-228 · Drug: TAK-117
TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
Drug: TAK-228 · Drug: TAK-117
TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
Drug: TAK-228 · Drug: TAK-117
TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
Drug: TAK-228 · Drug: TAK-117
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.
Time frame: From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)
Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort
Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort
Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation Cohort
Time frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Peak to Trough Ratio for TAK-228 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Peak to Trough Ratio for TAK-117 in DDI Expansion Cohort
Time frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.
Time frame: Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)
Duration of Response (DOR)
The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.
Time frame: Baseline, Days 22 up to Day 28 of Cycle and every even-numbered cycle until disease progression or EOS (Up to approximately 68 weeks)
Participants took part in the study at 5 investigative sites in Spain, United Kingdom and United States from 28 June 2013 to 30 April 2018.
| Milestone | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 3 | 7 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 16 | 7 | 14 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 3 | 7 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 16 | 7 | 14 | 20 |
| Withdrew: Progressive disease | 4 | 0 | 3 | 0 | 3 | 1 | 1 | 1 | 4 | 3 | 12 | 5 | 8 | 17 |
| Withdrew: Adverse event | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 2 | 0 | 3 | 1 | 2 | 2 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above-mentioned criteria.
| Participants | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 7 | 3 | 7 | 3 | 5 | 3 | 3 | 3 | 6 | 3 | 16 | 7 | 14 | 19 |
| SAEs | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 9 |
| hour | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 1.000 (0.50 to 4.00) | 1.000 (0.97 to 1.03) | 1.000 (0.50 to 4.07) | 2.050 (0.53 to 2.07) | 1.033 (1.00 to 2.08) | 2.083 (1.97 to 4.02) | 1.000 (0.48 to 1.07) | 1.067 (1.03 to 8.12) | 1.358 (0.50 to 4.00) | 1.067 (0.98 to 3.83) | 1.000 (0.50 to 2.15) | 0.725 (0.43 to 2.08) | 0.983 (0.47 to 4.17) |
| Cycle 1, Day 24 | 1.000 (0.50 to 2.00) | 0.758 (0.48 to 1.03) | 1.400 (0.45 to 4.08) | — | 2.000 (0.92 to 2.25) | 4.000 (1.00 to 4.12) | 1.408 (1.00 to 1.82) | 0.617 (0.48 to 2.00) | 0.925 (0.50 to 2.15) | 4.000 (4.000 to 4.000) | 1.033 (0.47 to 2.30) | 2.083 (1.95 to 4.87) | 1.017 (0.50 to 7.03) |
| ng/mL | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 24.63 ± 7.355 | 39.73 ± 7.853 | 25.80 ± 8.188 | 28.67 ± 3.702 | 18.26 ± 8.610 | 21.69 ± 29.273 | 48.90 ± 28.157 | 33.30 ± 16.301 | 53.10 ± 7.257 | 53.53 ± 29.788 | 42.17 ± 11.495 | 27.53 ± 11.665 | 26.51 ± 12.788 |
| Cycle 1, Day 24 | 27.78 ± 6.632 | 53.55 ± 2.192 | 29.45 ± 9.746 | — | 13.75 ± 6.938 | 37.36 ± 49.078 | 46.10 ± 17.253 | 72.43 ± 13.094 | 61.58 ± 14.894 | 17.1 ± 0 | 50.68 ± 12.055 | 17.75 ± 4.865 | 35.59 ± 18.415 |
| ng*hr/mL | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 120.888 ± 36.1184 | 247.361 ± 156.0211 | 138.929 ± 37.3727 | 230.983 ± 14.6292 | 109.622 ± 45.6613 | 126.062 ± 120.8204 | 303.897 ± 152.5659 | 287.283 ± 268.7088 | 351.602 ± 122.6407 | 382.588 ± 250.2623 | 249.341 ± 128.4868 | 168.408 ± 103.9245 | 160.670 ± 90.6815 |
| Cycle 1, Day 24 | 206.418 ± 169.5373 | 208.389 ± 78.6461 | 200.762 ± 56.1368 | — | 115.884 ± 50.7913 | 203.836 ± 120.1336 | 410.604 ± 265.8768 | 535.365 ± 256.8762 | 331.286 ± 133.7879 | 305.97 ± 0 | 317.111 ± 151.6045 | 132.058 ± 71.7154 | 211.792 ± 100.9091 |
| hour | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 5.090 ± 2.1653 | 5.783 ± 3.3941 | 6.214 ± 2.6649 | 7.450 ± 0.7368 | 6.975 ± 1.0108 | 4.65 ± 0 | 8.412 ± 1.3996 | 4.96 ± 0 | 5.792 ± 3.4405 | 6.799 ± 5.5740 | 6.320 ± 1.7839 | 5.512 ± 2.1598 | 7.593 ± 1.1365 |
| Cycle 1, Day 24 | 5.489 ± 2.4782 | 4.686 ± 2.1265 | 5.521 ± 1.6417 | — | 7.635 ± 1.1253 | 5.43 ± 0 | 8.5 ± 0 | 6.808 ± 1.7326 | 6.221 ± 1.0591 | — | 5.940 ± 1.6737 | 6.42 ± 0 | 6.354 ± 1.9320 |
| L/hour | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 16.534 ± 5.4762 | 19.049 ± 11.8558 | 14.419 ± 7.5636 | 7.694 ± 0.5750 | 15.311 ± 3.6762 | 11.38 ± 0 | 10.728 ± 6.9669 | 28.54 ± 0 | 19.999 ± 10.0509 | 16.259 ± 9.3725 | 17.924 ± 9.5261 | 22.715 ± 14.7252 | 13.933 ± 5.4880 |
| Cycle 1, Day 24 | 14.720 ± 4.5824 | 18.207 ± 4.1819 | 10.597 ± 3.9917 | — | 15.683 ± 2.9149 | 9.23 ± 0 | 13.58 ± 0 | 12.817 ± 4.7929 | 19.060 ± 7.1913 | — | 14.196 ± 5.3137 | 15.53 ± 0 | 16.133 ± 8.6701 |
Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].
| ratio | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAC: Accumulation Ratio for TAK-228 in the Dose Escalation Cohort | 2.225 ± 1.4576 | 1.25 ± 0 | 1.495 ± 0.1884 | — | 1.219 ± 0.3497 | 1.569 ± 0.4099 | 1.712 ± 0.2650 | 1.718 ± 0.4329 | 1.015 ± 0.1453 | 1.58 ± 0 | 1.172 ± 0.3363 | 1.213 ± 0.1306 | 1.461 ± 0.2246 |
| ratio | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 16.546 ± 6.5659 | 13.588 ± 8.3649 | 14.553 ± 6.8807 | 10.420 ± 1.5662 | 13.983 ± 6.6782 | 23.757 ± 31.1525 | 14.336 ± 7.0986 | 20.212 ± 22.0357 | 13.227 ± 8.3834 | 5.761 ± 1.5250 | 22.676 ± 14.2142 | 15.012 ± 6.5253 | 10.725 ± 2.7876 |
| Cycle 1, Day 24 | 12.145 ± 6.0465 | 27.66 ± 0 | 14.691 ± 8.1076 | — | 9.363 ± 6.6336 | 21.864 ± 33.1541 | 9.305 ± 4.7969 | 21.979 ± 13.7911 | 31.971 ± 19.6410 | 1.8 ± 0 | 22.555 ± 10.4006 | 8.805 ± 7.3805 | 21.157 ± 14.9668 |
| hour | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 0.800 (0.50 to 2.03) | 2.000 (1.03 to 2.00) | 2.050 (0.52 to 4.08) | 2.050 (1.03 to 2.07) | 3.017 (1.85 to 7.50) | 1.97 (1.97 to 1.97) | 2.000 (1.07 to 4.18) | 1.033 (0.50 to 8.12) | 4.008 (0.50 to 7.25) | 3.883 (2.42 to 7.33) | 1.925 (1.00 to 4.15) | 2.083 (0.95 to 6.03) | 3.125 (0.50 to 22.58) |
| Cycle 1, Day 24 | 1.000 (0.55 to 4.00) | 1.025 (1.02 to 1.03) | 4.108 (0.93 to 8.02) | — | 2.417 (1.97 to 4.00) | 2.000 (1.92 to 4.00) | 1.408 (1.00 to 1.82) | 0.883 (0.62 to 4.05) | 3.150 (2.00 to 7.02) | 7.33 (7.33 to 7.33) | 2.000 (1.00 to 8.02) | 2.050 (1.40 to 4.27) | 1.117 (0.95 to 8.07) |
| ng/mL | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 1800.0 ± 1049.25 | 988.7 ± 858.57 | 3067.1 ± 1243.50 | 4950.0 ± 3381.06 | 4136.7 ± 1487.68 | 2420 ± 0 | 3836.7 ± 656.07 | 1631.3 ± 1305.25 | 2711.7 ± 1172.97 | 2568.7 ± 2107.04 | 3369.4 ± 1417.31 | 3077.7 ± 1629.05 | 3353.0 ± 1955.02 |
| Cycle 1, Day 24 | 2514.0 ± 1597.13 | 2720.0 ± 1286.93 | 3438.3 ± 1687.00 | — | 3624.0 ± 2925.79 | 1054.8 ± 1454.94 | 6180.0 ± 127.28 | 4876.7 ± 848.84 | 4477.5 ± 953.88 | 100 ± 0 | 4863.3 ± 1142.54 | 3755.0 ± 2831.78 | 4805.3 ± 2893.99 |
| ng*hr/mL | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 14586.139 ± 10434.5445 | 11550.908 ± 11672.0852 | 43948.190 ± 25421.3428 | 69617.994 ± 46233.0898 | 54993.211 ± 27446.4517 | 26746.78 ± 0 | 47803.262 ± 4758.7418 | 23148.610 ± 27836.8878 | 38563.109 ± 23484.8077 | 39903.517 ± 33243.1212 | 38224.835 ± 22368.0163 | 30925.255 ± 15126.4913 | 46451.606 ± 33137.8861 |
| Cycle 1, Day 24 | 31723.844 ± 38363.4872 | 22566.251 ± 13562.8900 | 50960.181 ± 32295.5320 | — | 46278.615 ± 48171.7982 | 12428.783 ± 16745.7861 | 90462.795 ± 14090.4676 | 67186.097 ± 49493.0584 | 55908.919 ± 39888.9699 | 1674.23 ± 0 | 72432.560 ± 27615.6802 | 46164.679 ± 37938.0208 | 70490.572 ± 58515.7794 |
| hour | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 6.590 ± 3.4673 | 4.92 ± 0 | — | — | — | — | — | 3.839 ± 3.5498 | 7.465 ± 2.2023 | — | 4.858 ± 2.7928 | 6.379 ± 1.5369 | 7.368 ± 0.3774 |
| Cycle 1, Day 24 | 5.722 ± 3.1259 | 6.53 ± 0 | 2.98 ± 0 | — | 3.2 ± 0 | 8.37 ± 0 | — | 6.233 ± 4.4813 | 4.61 ± 0 | — | 7.717 ± 2.6428 | 5.853 ± 2.1534 | 5.984 ± 3.6558 |
| L/hr | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 16.993 ± 23.6496 | 9.79 ± 0 | — | — | — | — | — | 194.998 ± 258.2751 | 20.944 ± 16.6625 | — | 17.879 ± 17.8072 | 21.075 ± 16.4116 | 32.455 ± 35.8687 |
| Cycle 1, Day 24 | 13.821 ± 16.5047 | 7.18 ± 0 | 17.95 ± 0 | — | 9.25 ± 0 | 19.7 ± 0 | — | 5.328 ± 1.2794 | 5.45 ± 0 | — | 4.803 ± 2.7599 | 11.199 ± 8.4334 | 67.750 ± 110.0873 |
Accumulation ratio was based on AUC(0-24) between Cycle 1 Day 24 and Cycle 1 Day 1 (e.g. AUC(0-24) \[Cycle 1 Day 24\]/ AUC(0-24) \[Cycle1 Day 1\].
| ratio | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAC: Accumulation Ratio for TAK-117 in the Dose Escalation Cohort | 0.965 ± 0.1423 | 1.33 ± 0 | 1.161 ± 0.2506 | — | 1.049 ± 0.9033 | 1.18 ± 0 | 2.007 ± 0.4766 | 2.687 ± 0.5700 | 1.748 ± 1.1575 | 0.91 ± 0 | 1.879 ± 1.5772 | 0.925 ± 0.6281 | 4.183 ± 5.8060 |
| ratio | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 | 20.138 ± 21.6013 | 8.845 ± 7.8516 | 2.551 ± 0.9673 | 2.676 ± 0.1635 | 4.373 ± 3.3285 | 3.93 ± 0 | 3.602 ± 0.8361 | 6.640 ± 7.3746 | 6.877 ± 8.8600 | 2.631 ± 0.5993 | 6.872 ± 8.3680 | 11.494 ± 10.9430 | 3.426 ± 2.3804 |
| Cycle 1, Day 24 | 10.023 ± 9.0435 | 11.256 ± 7.1426 | 2.294 ± 0.5975 | — | 20.124 ± 33.8991 | 3.931 ± 2.4369 | 3.464 ± 0.1399 | 54.242 ± 87.1445 | 11.832 ± 15.4766 | 1.96 ± 0 | 5.482 ± 6.7075 | 11.184 ± 8.0869 | 4.664 ± 3.9973 |
| hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 1.000 (0.38 to 4.08) |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 0.983 (0.42 to 2.02) |
| ng/mL | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 60.02 ± 21.808 |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 71.99 ± 22.546 |
| ng*hr/mL | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 301.613 ± 123.9584 |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 390.307 ± 155.3378 |
| hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 6.823 ± 2.1608 |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 6.546 ± 1.8351 |
| L/hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled)) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 15.368 ± 10.9714 |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 13.359 ± 11.3718 |
| ratio | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 3, TAK-228 administered alone | 22.982 ± 11.6286 |
| Cycle 1, Day 10, TAK-228 administered with TAK-117 | 23.931 ± 15.6395 |
| hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 1.033 (0.50 to 4.12) |
| Cycle 1, Day 17, TAK-117 administered alone | 1.983 (0.50 to 7.25) |
| ng/mL | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 5357.3 ± 2842.40 |
| Cycle 1, Day 17, TAK-117 administered alone | 5332.6 ± 2955.51 |
| ng*hr/mL | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 61148.949 ± 42799.7918 |
| Cycle 1, Day 17, TAK-117 administered alone | 63975.156 ± 53764.5716 |
| hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 6.420 ± 2.3635 |
| Cycle 1, Day 17, TAK-117 administered alone | 5.717 ± 2.3715 |
| L/hour | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 11.797 ± 18.0040 |
| Cycle 1, Day 17, TAK-117 administered alone | 9.134 ± 8.7741 |
| ratio | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|
| Cycle 1, Day 10, TAK-117 administered with TAK-228 | 7.423 ± 7.423 |
| Cycle 1, Day 17, TAK-117 administered alone | 21.357 ± 44.3461 |
ORR defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT or MRI. CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter (LD) of target lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.
| percentage of participants | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Investigator's Assessment According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 |
The DOR is defined as the time from the date of first documented response of CR/PR to the first documented progressive disease (PD), or censored at the last response assessment date that is SD or better for a participant that has not progressed. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.
| days | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | — | — | — | — | — | — | — | — | — | — | — | — | — | 92 (1 to 288) |
Collected over Baseline up to 30 days after the last dose of study drug (Up to approximately 68 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Treatment Arm A: Cohort 1A | 0/7 (0%) | 2/7 (28.6%) | 6/7 (85.7%) |
| Dose Escalation Treatment Arm A: Cohort 2A | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation Treatment Arm A: Cohort 3A | 1/7 (14.3%) | 1/7 (14.3%) | 7/7 (100%) |
| Dose Escalation Treatment Arm A: Cohort 3A (Milled) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Treatment Arm A: Cohort 4A | 1/6 (16.7%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Dose Escalation Treatment Arm B: Cohort 1B | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation Treatment Arm B: Cohort 2B | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Treatment Arm B: Cohort 3B | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Treatment Arm B: Cohort 3B (Milled) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Escalation Treatment Arm B: Cohort 4B | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Treatment Arm B: Cohort 5B (Milled) | 2/16 (12.5%) | 4/16 (25%) | 16/16 (100%) |
| Dose Escalation Treatment Arm C: Cohort 1C | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Escalation Treatment Arm C: Cohort 2C (Milled) | 0/14 (0%) | 6/14 (42.9%) | 13/14 (92.9%) |
| Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | 2/20 (10%) | 9/20 (45%) | 19/20 (95%) |
| Event | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GastritisGastrointestinal disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Tumour fistulisationNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/6 | 1/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Ischaemic strokeNervous system disorders | 0/7 | 0/3 | 0/7 | 1/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Nerve compressionNervous system disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 1/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Intestinal perforationGastrointestinal disorders | 0/7 | 0/3 | 0/7 | 0/3 | 1/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 1/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Bile duct obstructionHepatobiliary disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 1/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Neutrophil count decreasedInvestigations | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 1/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| EnterocolitisGastrointestinal disorders | 1/7 | 0/3 | 0/7 | 0/3 | 0/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Event | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/7 | 2/3 | 6/7 | 3/3 | 4/6 | 1/3 | 3/3 | 3/3 | 5/6 | 3/3 | 11/16 | 4/7 | 10/14 | 11/20 |
| VomitingGastrointestinal disorders | 1/7 | 1/3 | 5/7 | 2/3 | 3/6 | 0/3 | 2/3 | 2/3 | 4/6 | 3/3 | 8/16 | 2/7 | 9/14 | 9/20 |
| FatigueGeneral disorders | 3/7 | 3/3 | 3/7 | 1/3 | 3/6 | 3/3 | 2/3 | 1/3 | 2/6 | 2/3 | 6/16 | 2/7 | 6/14 | 4/20 |
| DiarrhoeaGastrointestinal disorders | 3/7 | 2/3 | 3/7 | 1/3 | 2/6 | 2/3 | 2/3 | 1/3 | 2/6 | 2/3 | 6/16 | 3/7 | 7/14 | 6/20 |
| StomatitisGastrointestinal disorders | 1/7 | 2/3 | 2/7 | 2/3 | 2/6 | 2/3 | 0/3 | 1/3 | 1/6 | 1/3 | 0/16 | 0/7 | 3/14 | 7/20 |
| ConstipationGastrointestinal disorders | 1/7 | 2/3 | 3/7 | 0/3 | 2/6 | 0/3 | 0/3 | 1/3 | 2/6 | 0/3 | 3/16 | 3/7 | 3/14 | 3/20 |
| Oral painGastrointestinal disorders | 1/7 | 2/3 | 1/7 | 0/3 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/3 | 1/16 | 0/7 | 0/14 | 0/20 |
| PainGeneral disorders | 0/7 | 0/3 | 0/7 | 0/3 | 0/6 | 2/3 | 0/3 | 0/3 | 0/6 | 0/3 | 0/16 | 0/7 | 0/14 | 0/20 |
| Aspartate aminotransferase increasedInvestigations | 1/7 | 2/3 | 3/7 | 1/3 | 3/6 | 2/3 | 0/3 | 1/3 | 3/6 | 1/3 | 1/16 | 1/7 | 3/14 | 2/20 |
| Alanine aminotransferase increasedInvestigations | 1/7 | 1/3 | 2/7 | 1/3 | 3/6 | 2/3 | 0/3 | 1/3 | 3/6 | 1/3 | 1/16 | 1/7 | 2/14 | 2/20 |
Safety population consisted of all enrolled participants who received at least 1 dose of any study drug.
| Age, Continuous(years) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 59.9 ± 6.31 | 69.3 ± 5.13 | 50.6 ± 14.05 | 66.7 ± 5.86 | 48.7 ± 11.66 | 74.3 ± 5.13 | 69.3 ± 14.15 | 68.3 ± 9.24 | 58.0 ± 7.72 | 68.3 ± 4.16 | 56.6 ± 9.69 | 53.3 ± 14.36 | 56.5 ± 6.97 | 63.4 ± 9.10 | 59.4 ± 10.96 |
| Sex: Female, Male(Participants) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 2 | 7 | 3 | 2 | 1 | 2 | 1 | 4 | 2 | 11 | 2 | 7 | 13 | 64 |
| Male | 0 | 1 | 0 | 0 | 4 | 2 | 1 | 2 | 2 | 1 | 5 | 5 | 7 | 7 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 4 | 8 |
| Not Hispanic or Latino | 7 | 2 | 7 | 3 | 5 | 3 | 3 | 2 | 5 | 2 | 13 | 7 | 13 | 9 | 81 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 7 | 12 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 7 | 2 | 7 | 3 | 5 | 3 | 3 | 3 | 4 | 3 | 13 | 4 | 14 | 19 | 90 |
| Black Or African American | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 5 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 3 | 1 | 2 | 1 | 11 |
| Spain | 0 | 0 | 1 | 0 | 3 | 0 | 1 | 0 | 3 | 1 | 5 | 1 | 4 | 12 | 31 |
| United States | 7 | 3 | 6 | 3 | 3 | 3 | 2 | 1 | 2 | 1 | 8 | 5 | 8 | 7 | 59 |
| Height(cm) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 164.0 ± 3.84 | 165.1 ± 5.08 | 161.6 ± 3.26 | 159.4 ± 7.73 | 169.8 ± 8.73 | 169.0 ± 12.86 | 157.3 ± 4.25 | 168.5 ± 15.02 | 168.3 ± 12.41 | 168.5 ± 8.30 | 168.7 ± 11.24 | 180.7 ± 9.35 | 170.7 ± 7.86 | 163.7 ± 7.64 | 167.3 ± 9.67 |
| Weight(kg) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.8 ± 9.11 | 78.4 ± 1.34 | 69.7 ± 14.20 | 49.8 ± 8.06 | 79.5 ± 19.91 | 67.6 ± 20.33 | 62.5 ± 15.32 | 73.7 ± 17.32 | 78.2 ± 22.65 | 79.3 ± 9.11 | 71.4 ± 13.00 | 79.9 ± 15.19 | 78.6 ± 17.55 | 64.6 ± 12.08 | 71.4 ± 15.63 |
| Body Mass Index (BMI)(kg/m^2) | Dose Escalation Treatment Arm A: Cohort 1A | Dose Escalation Treatment Arm A: Cohort 2A | Dose Escalation Treatment Arm A: Cohort 3A | Dose Escalation Treatment Arm A: Cohort 3A (Milled) | Dose Escalation Treatment Arm A: Cohort 4A | Dose Escalation Treatment Arm B: Cohort 1B | Dose Escalation Treatment Arm B: Cohort 2B | Dose Escalation Treatment Arm B: Cohort 3B | Dose Escalation Treatment Arm B: Cohort 3B (Milled) | Dose Escalation Treatment Arm B: Cohort 4B | Dose Escalation Treatment Arm B: Cohort 5B (Milled) | Dose Escalation Treatment Arm C: Cohort 1C | Dose Escalation Treatment Arm C: Cohort 2C (Milled) | Drug-Drug Interaction (DDI) Expansion Cohort (Milled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 23.7 ± 2.80 | 28.8 ± 2.09 | 26.7 ± 5.65 | 19.9 ± 5.06 | 27.3 ± 5.09 | 23.2 ± 3.36 | 25.4 ± 7.18 | 26.2 ± 6.76 | 27.2 ± 4.60 | 27.9 ± 3.11 | 25.2 ± 4.30 | 24.3 ± 3.27 | 27.0 ± 5.74 | 24.1 ± 4.06 | 25.4 ± 4.66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jun 2013 to primary completion in Jan 2017, 43 months.
Results were first posted in Oct 2019, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sapanisertib · Serabelisib
Millennium Pharmaceuticals, Inc. →